DTX3L (deltex 3 like), also known as BBAP (B-aggressive lymphoma and BAL1 binding partner), is an E3 ubiquitin ligase. This gene localizes to human chromosome 3q21. Its C-terminal shares high identity with deltex (DTX) family members and contains a RING domain.

deltex 3 like, E3 ubiquitin ligase

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

DTX3L (deltex 3 like) is responsible for controlling the subcellular localization of BAL1 (B-aggressive lymphoma 1) protein in a dynamic shuttling manner. The expressions of both these protein are high in host response diffuse large B-cell lymphoma (HR-DLBCL). This protein regulates DNA damage response by monoubiquitylating histone H4 at lysine 91 position. It functions as a binding partner of BAL and they are both up-regulated in chemoresistant lymphomas. This protein plays a role in the endosomal sorting of CXCR4, which is a GPCR (G-protein couple receptor). Crosstalk amongst proteins STAT1 (signal transducer and activator of transcription 1), DTX3L and ARTD-like mono-ADP-ribosyltransferases is involved in the proliferation and survival of prostate cancer cells. Thus, in prostate cancer of high risk tumors with elevated STAT1 signaling, targeting these proteins can improve the outcome of chemotherapy or radiation therapy.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST71515

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany